Antiretroviral therapy: new drugs, formulations, ideas, and strategies.

Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr (2010) 1.24

Role of Marine Natural Products in the Genesis of Antiviral Agents. Chem Rev (2015) 0.82

Computational investigation of the anti-HIV activity of Chinese medicinal formula Three-Huang Powder. Interdiscip Sci (2010) 0.81

Entry time effects and follow-on drug competition. Eur J Health Econ (2014) 0.76

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis (2015) 1.86

Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis (2013) 1.78

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet (2017) 0.98

Association between first-year virological response to raltegravir and long-term outcomes in treatment-experienced patients with HIV-1 infection. Antivir Ther (2014) 0.89

Evaluating the Efficacy of Therapies in COVID-19 Patients. Clin Infect Dis (2020) 0.75